400
Participants
Start Date
April 1, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
April 1, 2027
Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA)
Group A will receive oral TDF-FTC PrEP (using either event-driven or daily) for 9-months. After 9-months, participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP
Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)
Group B will receive CAB-LA for 9-months. After 9-months participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP.
Collaborators (1)
King's College London
OTHER
London School of Hygiene and Tropical Medicine
OTHER
Africa Health Research Institute
OTHER
Wits Health Consortium (Pty) Ltd
OTHER
University College, London
OTHER
Ministry of Health, Uganda
OTHER_GOV
Desmond Tutu HIV Foundation
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
MRC/UVRI and LSHTM Uganda Research Unit
OTHER